ClinicalTrials.gg
CompletedNCT00759109Updated Apr 7, 2017Results posted

Pegylated Alfa-2b Interferon Therapy of Patients With Hepatitis C-related Cirrhosis and High Liver Cell Proliferation (P02733/MK-4031-085)

A Phase 3 interventional study of Peginterferon alfa-2b and Observation (no treatment) in Carcinoma, Hepatocellular, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-04-07.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Carcinoma, Hepatocellular by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Carcinoma, Hepatocellular · Merck & Co., Inc.

Enrollment
9th of 14
150 · median 285
Started
2002
the only one that year
Phase 3
6 of 14
none open now
Registered
2nd of 14
by date

Among the 14 studies in Carcinoma, Hepatocellular by Merck & Co., Inc, this one is the 9th largest by enrollment, is the only one that started in 2002, is one of 6 in phase 3, and was the 2nd registered.

Carcinoma, Hepatocellular

3,650 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

None of the 14 studies in Carcinoma, Hepatocellular by Merck & Co., Inc is open now. The open studies under Carcinoma, Hepatocellular, anywhere →

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies in Carcinoma, Hepatocellular by Merck & Co., Inc as a file.
02

Study summary

This study aims to compare the role of peginterferon α-2b (50 μg/week) vs. control (no treatment) in the prevention of hepatocellular carcinoma, in adult patients with cirrhosis and initial signs of portal hypertension who did not respond to previous combined therapy with interferon alfa + ribavirin or peginterferon alfa + ribavirin or to interferon alfa monotherapy and with a high proliferation rate before entering the study. The duration of treatment will be 3 years, and the follow-up period will be 2 years.

03

Conditions studied

  • Carcinoma, Hepatocellular
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Cirrhotic participants, both sexes, A, B, positive, age \< 70 years
  • Participants non-responders to IFN + Ribavirin or PegIFN + Ribavirin or IFN monotherapy
  • Pre-therapy liver (\< 36 months) with PCNA-LI > 2.0
  • Fibrosis score 5-6 (Ishak)
  • Initial portal hypertension, such as gastroesophageal varices or one of the following US sign:

    • Collateral circles
    • Spleen longitudinal diameter > 12 cm
    • Portal vein diameter at hilus > 12 mm
    • Portal flow > 12 cm/sec
    • Participants must have the following minimum hematologic and biochemical criteria:
    • >= 11 g/dL
    • Granulocyte count > 1,000/mm\^3
    • > 70,000/mm\^3
    • Prothrombin activity > 50%
    • Total \<3 mg/dL
    • Albumin >= 3.5 g/dL
    • Serum creatinine within normal limits
  • Uric Acid within normal limits
  • Thyroid Stimulating Hormone (TSH), within normal limits
  • Antinuclear antibodies (ANA) \< 1:160
  • Written
  • Women of must have a negative pregnancy test
  • Acceptance of patients of both sexes of proper measures for the study period

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breast-feeding women
  • Co-infection with and/or
  • hepatitis or history of autoimmune disease
  • Alcoholic liver disease
  • Metabolic disease
  • HCC
  • Participants with liver and kidney transplants
  • Evidence of decompensated liver disease such as history or presence of ascites, bleeding varices, spontaneous encephalopathy
  • Chronic renal failure or \< 50 mL/min
  • Pre-existing thyroid disease unless it can be controlled with conventional treatment
  • History or presence of psychiatric condition, especially depression, or a history of severe psychiatric disorder, such as major psychoses, suicidal ideation and/or suicidal attempt
  • Epilepsy and/or compromised central nervous system (CNS) function
  • Significant cardiovascular dysfunction within the previous 6 months before the study starts (eg, angina, congestive heart failure, recent myocardial infarction, moderate or severe hypertension, significant arrhythmia)
  • Hemoglobinopathies
  • Poorly controlled diabetes mellitus
  • Chronic pulmonary disease (eg, )
  • Clinical gout
  • to interferons or any component of the drug
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (actual)

Study arms

  • Experimental
    Arm A - PegIntron

    Participants randomized to Arm A received peginterferon α-2b (PegIntron), 50 μg, weekly, subcutaneously (SC), for a period of 3 years.

    Biological: Peginterferon alfa-2b

  • Other
    Arm B - Control

    Participants randomized to Arm B were under observation and received no treatment.

    Other: Observation (no treatment)

Interventions

  • Peginterferon alfa-2b, 50 μg, weekly, SC, for a period of 3 years.

    Also known as: PegIntron, Pegylated Alfa-2b, SCH 054031

  • OtherObservation (no treatment)

    No treatment was given to participants enrolled in the control arm (Arm B).

06

What researchers measure

Primary outcomes

  1. Number of Participants With the Development of Hepatocellular Carcinoma (HCC)

    Participants were tested for focal lesions by liver ultrasound and for AFP levels every 6 months the during study (treatment and follow-up). The development of hepatocellular carcinoma was determined by: 1. the appearance of a focal lesion detected by liver ultrasound with metastases confirmed by fine needle biopsy, or 2. the appearance of a focal lesion detected by ultrasound + alphafetoprotein (AFP) levels in blood \>400 ng/mL.

    Time frame: During 3 years of treatment and 2 years of follow-up

Secondary outcomes

  1. Number of Participants With Development of Hepatic Decompensation

    The development of hepatic decompensation, defined as worsening of the hepatic function as measured by Child Pugh Score. The Child Pugh score was calculated based on biochemical changes (changes in serum albumin, serum bilirubin, prothrombin time) and clinical impairment (ascites, encephalopathies) or both. Each of the 5 parameters was scored from 1-3, and the Child Pugh Score represented the total score. The maximum score was 15, and a score of 10-15 represents the worst outcome and a life expectancy of 1-3 years.

    Time frame: Baseline, During 3 years of treatment and 2 years of follow-up

  2. Survival Time of Participants

    Survival time was defined as time from screening visit to the death of the participant and was studied with Kaplan-Meier and Log-rank tests. If a participant did not die, he or she was censored with the last available date.

    Time frame: During 3 years of treatment and 2 years of follow-up

  3. Number of Patients With a Virological Response Rate

    Virological Response rate was measured by the disappearance of Hepatitis C Virus from serum. Serum samples from participants were analyzed for the presence of HCV-RNA using a qualitative polymerase chain reaction (PCR).

    Time frame: Baseline and every year during 3 years of treatment

  4. Change in the Proliferating Cell Nuclear Antigen Labeling Index (PCNA-LI)

    PCNA-LI was measured at baseline and at 18 months of treatment, and the change in PCNA-LI was calculated. To measure PCNA-LI, liver tissue samples obtained from biopsies were fixed and immunostained to detect PCNA. PCNA-LI is the percentage of immunohistochemically stained (PCNA positive) cells in 1,000 HCC cells counted. A higher PCNA-LI indicates a worse outcome.

    Time frame: Baseline and at 18 months of treatment

Other outcomes

  1. Proliferating Cell Nuclear Antigen Labeling Index (PCNA-LI) at Baseline

    Liver tissues obtained from biopsies were fixed and immunostained to detect PCNA. PCNA-LI is the percentage of immunohistochemically stained (PCNA positive) cells in 1,000 HCC cells counted. A higher PCNA-LI indicates a worse outcome.

    Time frame: Baseline

07

Results

Posted Apr 18, 2011

Participant flow

Participant flow — Overall Study
MilestoneArm A - PegIntronArm B - Control
Started7476
Completed3541
Not completed3935
Withdrew: Adverse event1712
Withdrew: Inability to comply11
Withdrew: Withdrawal by subject95
Withdrew: Death43
Withdrew: Lost to follow-up46
Withdrew: Started new therapy26
Withdrew: Hcv rna negative10
Withdrew: Participant moved to a different city01
Withdrew: Participant had a liver transplant01
Withdrew: Lost during study10

Outcome measures

PrimaryNumber of Participants With the Development of Hepatocellular Carcinoma (HCC)

Participants were tested for focal lesions by liver ultrasound and for AFP levels every 6 months the during study (treatment and follow-up). The development of hepatocellular carcinoma was determined by: 1. the appearance of a focal lesion detected by liver ultrasound with metastases confirmed by fine needle biopsy, or 2. the appearance of a focal lesion detected by ultrasound + alphafetoprotein (AFP) levels in blood \>400 ng/mL.

Time frame:
During 3 years of treatment and 2 years of follow-up
Reported as:
Number · Participants
Number of Participants With the Development of Hepatocellular Carcinoma (HCC)
ParticipantsArm A - PegIntronArm B - Control
Number of Participants With the Development of Hepatocellular Carcinoma (HCC)1511
SecondaryNumber of Participants With Development of Hepatic Decompensation

The development of hepatic decompensation, defined as worsening of the hepatic function as measured by Child Pugh Score. The Child Pugh score was calculated based on biochemical changes (changes in serum albumin, serum bilirubin, prothrombin time) and clinical impairment (ascites, encephalopathies) or both. Each of the 5 parameters was scored from 1-3, and the Child Pugh Score represented the total score. The maximum score was 15, and a score of 10-15 represents the worst outcome and a life expectancy of 1-3 years.

Time frame:
Baseline, During 3 years of treatment and 2 years of follow-up
Reported as:
Number · Participants
Number of Participants With Development of Hepatic Decompensation
ParticipantsArm A - PegIntronArm B - Control
Number of Participants With Development of Hepatic Decompensation49
SecondarySurvival Time of Participants

Survival time was defined as time from screening visit to the death of the participant and was studied with Kaplan-Meier and Log-rank tests. If a participant did not die, he or she was censored with the last available date.

Time frame:
During 3 years of treatment and 2 years of follow-up
Reported as:
Median · Years
Survival Time of Participants
YearsArm A - PegIntronArm B - Control
Survival Time of Participants5.2840 (3.0116 to 5.2841)4.0602 (NA to NA)
SecondaryNumber of Patients With a Virological Response Rate

Virological Response rate was measured by the disappearance of Hepatitis C Virus from serum. Serum samples from participants were analyzed for the presence of HCV-RNA using a qualitative polymerase chain reaction (PCR).

Time frame:
Baseline and every year during 3 years of treatment
Reported as:
Number · Participants
Number of Patients With a Virological Response Rate
ParticipantsArm A - PegIntronArm B - Control
Baseline00
1 year30
2 years10
3 years00
SecondaryChange in the Proliferating Cell Nuclear Antigen Labeling Index (PCNA-LI)

PCNA-LI was measured at baseline and at 18 months of treatment, and the change in PCNA-LI was calculated. To measure PCNA-LI, liver tissue samples obtained from biopsies were fixed and immunostained to detect PCNA. PCNA-LI is the percentage of immunohistochemically stained (PCNA positive) cells in 1,000 HCC cells counted. A higher PCNA-LI indicates a worse outcome.

Time frame:
Baseline and at 18 months of treatment
Reported as:
Mean · Score on a scale
Change in the Proliferating Cell Nuclear Antigen Labeling Index (PCNA-LI)
Score on a scaleArm A - PegIntronArm B - Control
Change in the Proliferating Cell Nuclear Antigen Labeling Index (PCNA-LI)-2.0 ± 3.2-0.9 ± 2.4
Other pre-specifiedProliferating Cell Nuclear Antigen Labeling Index (PCNA-LI) at Baseline

Liver tissues obtained from biopsies were fixed and immunostained to detect PCNA. PCNA-LI is the percentage of immunohistochemically stained (PCNA positive) cells in 1,000 HCC cells counted. A higher PCNA-LI indicates a worse outcome.

Time frame:
Baseline
Reported as:
Mean · Score on a scale
Proliferating Cell Nuclear Antigen Labeling Index (PCNA-LI) at Baseline
Score on a scaleArm A - PegIntronArm B - Control
Proliferating Cell Nuclear Antigen Labeling Index (PCNA-LI) at Baseline4.2 ± 2.13.9 ± 1.6

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A - PegIntron—36/74 (48.6%)55/74 (74.3%)
Arm B - Control—30/76 (39.5%)36/76 (47.4%)
Most frequent serious events
Showing 10 of 80
Most frequent serious events
EventArm A - PegIntronArm B - Control
HEPATIC NEOPLASM MALIGNANTNeoplasms benign, malignant and unspecified (incl cysts and polyps)15/7411/76
CEREBRAL HAEMORRHAGENervous system disorders4/740/76
ASCITESGastrointestinal disorders2/742/76
HEPATIC FAILUREHepatobiliary disorders2/741/76
EPILEPSYNervous system disorders2/740/76
THORACIC VERTEBRAL FRACTUREInjury, poisoning and procedural complications0/742/76
BREAST CANCERNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/742/76
THROMBOCYTOPENIABlood and lymphatic system disorders1/740/76
ACUTE MYOCARDIAL INFARCTIONCardiac disorders1/740/76
CONGESTIVE CARDIOMYOPATHYCardiac disorders1/740/76
Most frequent other events
Showing 10 of 21
Most frequent other events
EventArm A - PegIntronArm B - Control
ASTHENIAGeneral disorders21/747/76
INFLUENZA LIKE ILLNESSGeneral disorders20/741/76
HEADACHENervous system disorders11/740/76
HYPERTENSIONVascular disorders5/7410/76
PYREXIAGeneral disorders7/742/76
ASCITESGastrointestinal disorders1/747/76
OEDEMA PERIPHERALGeneral disorders5/747/76
WEIGHT DECREASEDInvestigations6/741/76
BACK PAINMusculoskeletal and connective tissue disorders6/741/76
DEPRESSIONPsychiatric disorders6/740/76

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Arm A - PegIntronArm B - ControlTotal
Mean57 ± 8.759.7 ± 7.258.3 ± 8.1
Sex: Female, Male
Sex: Female, Male(Participants)Arm A - PegIntronArm B - ControlTotal
Female223456
Male523890
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2002, a primary completion of Nov 2009 and a completion of Nov 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2011, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2008
First posted
Sep 25, 2008
Start
Mar 2002
Primary completionActual
Nov 2009
CompletionActual
Nov 2009
Results first posted
Apr 18, 2011
Last update
Apr 7, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00759109
Responsible party
Sponsor
First posted
Sep 25, 2008
Start date
Mar 2002
Primary completion
Nov 2009
Completion
Nov 2009
Results posted
Apr 18, 2011
Last update
Apr 7, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Peginterferon alfa-2b

Start the discussion